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The Adjuvant System AS01 contains monophosphoryl lipid A (MPL) and the saponin QS-
21 in a liposomal formulation. AS01 is included in recently developed vaccines against
malaria and varicella zoster virus. Like for many other adjuvants, induction of adaptive
immunity by AS01 is highly dependent on the ability to recruit and activate dendritic cells
(DCs) that migrate to the draining lymph node for T and B cell stimulation. The objective of
this study was to more precisely address the contribution of the different conventional
(cDC) and monocyte-derived DC (MC) subsets in the orchestration of the adaptive
immune response after immunization with AS01 adjuvanted vaccine. The combination
of MPL and QS-21 in AS01 induced strong recruitment of CD26+XCR1+ cDC1s,
CD26+CD172+ cDC2s and a recently defined CCR2-dependent CD64-expressing
inflammatory cDC2 (inf-cDC2) subset to the draining lymph node compared to antigen
alone, while CD26-CD64+CD88+ MCs were barely detectable. At 24 h post-vaccination,
cDC2s and inf-cDC2s were superior amongst the different subsets in priming antigen-
specific CD4+ T cells, while simultaneously presenting antigen to CD8+ T cells. Diphtheria
toxin (DT) mediated depletion of all DCs prior to vaccination completely abolished adaptive
immune responses, while depletion 24 h after vaccination mainly affected CD8+ T cell
responses. Vaccinated mice lacking Flt3 or the chemokine receptor CCR2 showed a
marked deficit in inf-cDC2 recruitment and failed to raise proper antibody and T cell
responses. Thus, the adjuvant activity of AS01 is associated with the potent activation of
subsets of cDC2s, including the newly described inf-cDC2s.
Keywords: AS01, vaccine, adjuvant, dendritic cell, inf-cDC2, CD64, MAR-1, Fc receptorAbbreviations: For more information on LSIDs please see Inclusion of Zoological Nomenclature section of the guidelines.
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Bosteels et al. AS01 Activity Relies on inf-cDC2sINTRODUCTION
Recombinant proteins are often combined with adjuvants in
vaccines to enhance immunogenicity with the aim of conferring
protection against disease. Similar to natural infections, adjuvants
trigger the innate immune system, which in turn shapes the nature
of the adaptive immune response. The Adjuvant System AS01 is a
liposome-based adjuvant that contains two immunostimulants (1).
The first compound 3-O-desacyl-4’-monophosphoryl lipid A
(MPL) is a detoxified lipid from Salmonella Minnesota LPS and a
Toll-like receptor 4 (TLR4) agonist (2). MPL promotes the
production of pro-inflammatory cytokines and directly activates
antigen-presenting cells (APCs) (3, 4). The second compound, QS-
21, is a saponin molecule extracted from the bark of the Quillaja
saponaria tree (1). QS-21 enhances antibody responses in humans
(5), and cytotoxic CD8+ T lymphocyte (CTL) responses in mice
throughmodified antigen cross-presentation by cDCs (6–8).QS‐21
activates innate immunity through destabilization of the lysosomal
membrane upon cholesterol‐dependent endocytosis, leading to the
activation of the caspase‐1 and Syk pathways (6, 7). By activating
multiple innate pathways, both immunostimulants in AS01
synergistically enhance antigen-specific T cell responses
producing interferon-gamma (IFN-g) and antibody switching
toward IgG2c antibodies in mice (3, 9, 10). We have previously
established that the ability of AS01 to induce a strong T cell
response relies on a synergy between MPL and QS-21 (9, 11).
The liposomal formulation of AS01 allows to improve the delivery
of the immunostimulants and to abrogate the hemolytic activity
of QS-21 (12). AS01 is included in the recombinant herpes zoster
(Shingrix) and the malaria vaccines (13–15) as well as in other
candidate vaccines against viruses and intracellular pathogens, such
as HIV and tuberculosis (16, 17).
The key cells to integrate and translate the innate cues elicited by
AS01 into antigen-specific effector responses are antigen-
presenting cells (APCs), and in particular conventional dendritic
cells (cDCs). Dendritic cells are classically subdivided in cDCs,
plasmacytoid DCs (pDCs) andmonocyte-derived DCs (moDCs or
MCs). Based on differences in transcriptional control, function,
ontogeny and cell surface markers, mature cDCs are further
subdivided into cDC1s and cDC2s (18–20). Functionally, cDC1s
have the capacity to present and cross-present antigen to CD8+ T
cells, whereas cDC2s typically drive naive CD4+ T cells toward
distinct effector subsets (21). While the cDC1 subset is precisely
delineated by the expression of specific markers (such as XCR1),
cDC2s seem more heterogenous on a transcriptional level and
express surface markers (such as CD172a, CD11b) that often
overlap with macrophages and MCs (22). Upon induction of
inflammation, tissue-infiltrating monocytes rapidly upregulate
major histocompatibility complex class II (MHCII) and CD11c,
to become so called MCs (or monocyte-derived DCs), that can be
easily confused with cDC2s (23–25). Importantly, we have recently
identified an activated cDC2 population, called inflammatory-
cDC2 (inf-cDC2) that acquires transcriptional, functional and
phenotypical characteristics traditionally defining cDC1s (e.g.
CD26, IL-12, and IRF8) and MCs (e.g. surface expression of
activating FcgR such as CD64 and MAR-1) in a cell-intrinsic,
type I interferon dependent manner. In our work on variousFrontiers in Immunology | www.frontiersin.org 2antigenic triggers (viruses, allergens, bacteria, helminths) in the
lung and skin, we described how these pre-cDC-derived hybrid inf-
cDC2s efficiently migrated to the dLN in a CCR7-dependent
manner to prime both naive CD4+ and CD8+ T cells, whereas
MCs were unable to do so. Consistent with the expression of
activating Fc receptors (i.e. CD64 and MAR-1), inf-cDC2s
competently endocytosed antibody–complexed antigen for
enhanced Th1 priming (23). Although dependency on the CCR2
chemokine receptor formonocyte bonemarrow egress was initially
considered as a defining characteristic of monocyte-derived cells
(26), we found that inf-cDC2s were also dependent on CCR2, and
cautioned that CCR2-dependency did not equalize with monocyte
origin (23).
The objective of this study was to assess the role played by the
different DC subsets in the orchestration of the adaptive immune
response raised against two antigens combined with AS01. We
have found that combining immunostimulants in AS01 adjuvant
results in recruitment of monocytes and DC subsets cDC1s,
cDC2s and inf-cDC2s to the dLN, while DC-like MCs were
barely detectable. Finally, our findings indicate that the recently
described inf-cDC2 subset, next to cDC1s and cDC2s, is essential
to confer both antigen-specific cellular and humoral immunity
induced by AS01-containing vaccine.MATERIAL AND METHODS
Mice
The following female mice were used in this study; C57BL/6 mice
(aged 6–10 weeks) were purchased from Janvier (France). CD45.1
(Jackson laboratories, StockNo: 002014), Itgax-DTR,OVA-specific
CD4+ TCR Tg (OTII; Jackson laboratories, Stock No: 004194),
OVA-specific CD8+ TCR Tg (OTI; Jackson laboratories, Stock No:
003831),Ccr2-/- (Jackson laboratories, StockNo: 027619) andFlt3-/-
mice were bred in house in specific pathogen-free conditions at
the animal facility of Ghent University. Animal husbandry and
experiments were ethically reviewed and carried out in accordance
with European Directive 2010/63/EU. All experiments were
approved by the independent animal ethical committee “Ethische
Commissie Dierproeven – faculteit Geneeskunde en Gezondheids-
wetenschappen Universiteit Gent”.
Vaccine Formulations and Mouse
Immunization
VZVgEantigen,AS01,MPL, andQS-21 formulationswere provided
by GSK, Rixensart, Belgium. Ovalbumin (OVA) was from
Calbiochem and confirmed to be endotoxin depleted. The gE
antigen and AS01 are components of the licensed recombinant
Zoster vaccine (Shingrix) and were produced in the same GMP
conditions for this study1. AS01 is composed of QS-21 (Quillaja
saponariaMolina, fraction 21, licensedbyGSK fromAntigenics LLC,
a wholly owned subsidiary of Agenus Inc., a Delaware, USA
corporation) and MPL in a liposome formulation made of Di-
Oleoyl Phosphatidyl Choline (DOPC) and cholesterol. Mice wereJanuary 2021 | Volume 11 | Article 606805
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at day 14. Each vaccine dose was administered as two simultaneous
i.m. injections of each 20–25 µl in both left and right gastrocnemius
muscles. Depending on the experiment (cfr. figure legends),
adjuvant dose per injection site was 1 or 2.5 µg AS01 or 1 µg MPL
or 1 µg QS-21, all formulated in the same liposome as used in AS01,
and combined with antigen(s) either VZV gE (2 or 2.5 µg per
injection site) or OVA (5 µg per injection site) or both VZV gE and
OVA together (respectively 2.5 µg and 0.5 µg per injection site).
Ex vivo DC-OTII CD4+ and OTI CD8+ T Cell
Co-Culture
Naive OVA-specific CD8+ and CD4+ T cells were isolated from
spleens of OTI and OTII transgenic mice, respectively, enriched
through negative selection for CD8+ and CD4+ T cells (EasySep)
and labeled with Cell proliferation dye eFluor450 (CTV, Thermo
Fisher Scientific) according to manufacturer’s instructions. DCs
isolated from the dLNs 24 h post-immunization with OVA/AS01
were enriched through negative selection (Dynabeads, Thermo
Fishser Scientific). A total of 25x103 OVA-specific T cells were
then separately co-cultured for 3 days (OTI) or 4 days (OTII) at
various ratios with the distinct migratory cDC subsets purified by
cell sorting using a FACSAria (> 95%purity) in sterile tissue culture
medium [TCM; RPMI (Gibco) containing 5% fetal calf serum
(Bodinco), 1.1 mg/ml b-mercaptoethanol (Sigma-Aldrich), 2 mM
L-alanyl-L-glutamine dipeptide (Thermo Fisher Scientific), and 56
mg/ml Gentamicin (Thermo Fisher Scientific)].
Tissue Sampling and Processing
Mice were euthanized at time points indicated by intraperitoneal
(i.p.) injection of sodium pentobarbital. Iliacal LNs were digested
in 1.2 ml RPMI (Gibco) containing 20 mg/ml Liberase and 10 U/
ml Dnase (Roche) for 20 min at 37°C before passing through a 70
mm cell strainer. Splenocytes were obtained by passing through a
70 µm filter and red blood cells were lysed using ammonium
chloride lysis buffer (10 mM KHCO3, 155 mM NH4Cl, 0.1 mM
EDTA in MilliQ water).
Flow Cytometry and Cell Sorting
Single cell suspensions were incubated with a mix of fluorescently
labeledmonoclonal antibodies (Ab) and/or tetramers (cfr. infra) for
30–45 min at 4°C. To reduce non-specific binding, 2.4G2 Fc
receptor Ab (Bioceros NV) was added. Dead cells were removed
from analysis, using fixable viability dye eFluor506 or eFluor780
(eBioscience). For intracellular staining cells were fixed and
permeabilized using Cytofix-Cytoperm and Perm/Wash (BD
Biosciences) according to the manufacturer’s protocol. In order to
monitor individual cell divisions of T cells, cells were stained with
Cell proliferation dye eFl450 (CTV, Thermo Fisher Scientific)
according to the manufacturer’s protocol. Cells were stained with
anti-mouse antibodies (see Supplementary Table). In a second
staining step, biotin-conjugated antibodies were bound by SAV-
CF594 (BD Biosciences). Before acquisition, photomultiplier tube
voltages were adjusted to minimize fluorescence spillover. Single-
stain controls were prepared with UltraComp eBeads (Thermo
Fisher Scientific) following the manufacturer’s instructions and
were used to calculate a compensation matrix. Sample acquisitionFrontiers in Immunology | www.frontiersin.org 3was performed on an LSR Fortessa or FACSymphony cytometer
equipped with FACSDiva software (BD biosciences). Final analysis
and graphical output were performed using FlowJo software
(Tree Star, Inc.) and GraphPad Prism 6 (GraphPad Software,
Inc.). For sorting of DC subsets and T cells, cells were stained as
described and cell sorting was performed on a FACSAria II and III
(BD biosciences).
Itgax-DTR Transgenic and WT : Ccr2-/-
Bone Marrow Chimeras
Bone marrow cells were prepared by crushing femurs and tibias in
phosphate buffer saline (PBS) followed by filtering through a sterile
70 mm cell strainer. C57BL/6 mice (8–10 wk old) were sublethally
irradiated (8Gy) and, 4h later, received 2x106 bonemarrowcells i.v.
from transgenic Itgax-DTR mouse donors (27). At least 10 weeks
after bonemarrowreconstitutionandeither 12hbeforeor24hafter
immunization, chimeric mice were depleted of CD11c+ cells by an
injection of 200 ng DT or PBS (control) in both gastrocnemius
muscles. In some experiments the immunization was performed
twicewith 14 days apart. CompetitiveCD45.1(WT): CD45.2Ccr2-/-
and CD45.1(WT): CD45.2 Ccr2+/+ bone marrow chimeras were
similarly generated by sublethally irradiating (8 Gy) CD45.1.2
C57BL/6 mice (8–10 wk old), that received 2x106 bone marrow
cells i.v. in a 50:50 ratio of CD45.1/CD45.2 donors 4 h later.
Antigen-Specific Antibody and T Cell
Response
Anti-VZV gE IgG concentrations in the serum were measured by
ELISA, following a protocol described previously (11, 27). The
frequency of SIINFEKL (OVA257–264)-specific CD8
+ T cells was
determined in peripheral blood or splenocytes by staining with PE-
conjugated H-2Kb-OVA257–264 tetramers (Beckman Coulter). Single
cell levels of cytokine production by antigen-specific T cell response
were measured as previously described (27, 28). Briefly, splenocytes
from vaccinated mice (2 x 106 cells/well in 96-well microplate) were
stimulated in vitro with VZV gE peptides (1 µg/ml; encompassing
whole antigen, 15-merswith11amino-residueoverlap;Eurogentec) or
OVApeptides (1µg/ml;pool consistsof17peptides selected forH2-Kb
epitope content, all are 15-mers with 11 amino-residue overlap;
Neosystem) in complete RPMI supplemented with 5% fetal calf
serum (FCS, Bodinco). Anti-CD49d (9C10) and anti-CD28 (37.51)
antibodies (1 µg/ml each, BD Biosciences) were added to the culture.
Antigens-specific stimulation of T cells wasmonitored by intracellular
cytokine staining after 18 h incubation at 37°C in which Brefeldin A
(1 mg/ml, BD Biosciences) was added for the last 16 h.
Cytokine Detection in Serum
Serumwas collected24hafter immunizationat stored at -70°Cuntil
further analysis. Cytokine protein levels were determined by
cytokine-specific beads using the Luminex platform (Millipore).
Statistical Analyses
Results are expressed asmean ± SEM as indicated in figure legends.
Statistical tests were selected based on appropriate assumptions
with respect to data distribution and variance characteristics. One-
wayANOVAwithSidak correction formultiple testingwas used for
the statistical analysis of differences betweenmore than two groups.January 2021 | Volume 11 | Article 606805
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analysis of differences between more than two groups and with 2
different independent variables. Statistical significance was defined
as p <0.05. Sample sizes were chosen according to standard
guidelines. Number of animals is indicated as “n”. Of note, sizes
of the tested animal groups were also dictated by availability of the
transgenic strains. Statistical details of experiments can be found in
the figure legends. The investigator was not blinded to the mouse
group allocation.RESULTS
cDC2 is the Main DC Subset Recruited Upon
Administration of AS01 or Its Components
We have previously reported in detail the kinetics of the innate
immune response in mice after intramuscular (i.m.) injection of
AS01-adjuvanted vaccines (27). Neutrophils, monocytes and DCs
rapidly [i.e. within 24 h post-injection (pi)] increase in the draining
iliacal LN (dLN) after i.m. immunization. Although adaptive
immunity induced by AS01-adjuvanted vaccine required CD11c+
cells, the relative contribution of the different DC subsets to the T
cellpriming effectofAS01or its componentswasnot assessed.Here,
we immunizedmice by i.m. injectionwith 2 µgVZV gE formulated
inAS01 (gE/AS01), inMPLalone (gE/MPL), or inQS-21 alone (gE/
QS-21). Twenty-four hours after immunization, we analyzed the
different DCs subsets in the dLN. We employed a universal gating
strategy to separate both Flt3-dependent cDC1s and cDC2s; and
Flt3-independent MCs within MHCIIhiCD11c+ cells based on
specific surface markers (22). We stained for the dipeptidyl
peptidase CD26, identifying all cDCs, whereas MCs were
identified as CD26-CD64+ cells also expressing the complement
receptorCD88 (22, 23, 29). XCR1 andCD172a (Sirpa)were used as
conserved markers to separate cDC1s from (CD11b+) cDC2s,
respectively (22). cDC1s characteristically expressed high levels of
CD24, while CD11b expression was restricted to cDC2s, inf-DC2s
and MCs (data not shown). Additionally, we stained for other
activating FcgRs besides CD64, and used MAR-1 staining to mark
inflammatory cDC2s andMCs in immunized mice (23, 25, 30, 31)
(Figures 1A–E).
In mice receiving AS01-adjuvanted vaccine (Figure 1A), there
was a marked increase in the total number of MHCIIhiCD11c+
migratory DCs in the draining iliac LN 24 h post injection,
compared with mice receiving antigen alone (Figures 1D, F).
This increase was also seen when MPL (gE/MPL) and QS-21 (gE/
QS-21) adjuvant components were used (Figures 1B, C, F). In all
conditions of vaccination, the bulk of MHCIIhiCD11c+ cells were
composed of CD26+ cDCs with only a very limited proportion of
CD26loCD64hiCD88hi MCs (Figures 1A–D, F). Within the cDC2
population, MAR-1+CD64+ inf-cDC2s were only detected in the
presence of AS01 or its components. In all groups migratory cDCs
weremainly composedof cDC2s, followedbycDC1sand inf-cDC2s
(Figures 1A–D, F).
In conditions of inflammation, myeloid markers often overlap
between various cell types. In line with our previous work (23),
CD88 was however exclusively expressed by MCs, while Ly6C
expression was shared between inf-cDC2s and MCs (Figure 1E).Frontiers in Immunology | www.frontiersin.org 4Upon activation, antigen-bearing cDCsmigrate to the draining LN
in a CCR7 dependentmanner (32, 33). Surface expression of CCR7
was induced upon immunization with gE/AS01 on cDC1s, cDC2s
and inf-cDC2s but not MCs (Figure 1E). CCR2 was mainly
expressed by MCs, less by cDC2s, while surface CCR2 expression
was hardly detectable on migratory cDC1s. Next to DCs, other
innate cells such as CD11b+Ly6C+MHCII- monocytes and
CD11b+Ly6G+ neutrophils were significantly increased in the
dLN 24 h pi with AS01-adjuvanted vaccine (Figure 1G).
Interestingly, MPL seems to induce DC recruitment more
efficiently than AS01 or QS-21, irrespective of the DC subsets,
while in contrast,QS-21performed relatively poorly as compared to
AS01 or MPL, especially for cDC1 recruitment (Figure 1F).
However, the combination of both MPL and QS-21 results in the
efficient recruitment of a variety of DC subsets. In contrast to cDCs
and although Ly6Chi monocytes heavily infiltrate the dLN upon
antigen immunization formulated in AS01 (27), we show here that
CD11c+MHCII+ MCs were barely detectable and expressed low
levels of CCR7 in accordance with their poor migratory capacity in
other tissues and immunization regimens (23).
All cDC Subsets can Efficiently Present
Antigens After Immunization with AS01-
Adjuvanted Vaccines
We have shown that association of AS01 to antigen activates the
innate immune system and leads to enhanced antigen-specific
adaptive immune responses (27). We extended this finding by
looking at the capacity of the different cDC subsets to prime naive T
cells. As afirst step,we investigated the altered activation state of the
different cDC subsets. All cDC subsets expressed higher levels of
costimulatory molecules such as CD40 and CD86 at 24 h pi with
Ovalbumin (OVA)/gE/AS01 compared to antigen alone, except
for inf-cDC2s (Figures 2A, B). The extent of upregulation of
costimulatory molecules by MPL was similar to AS01, and higher
compared to QS-21, suggesting that MPL is the main driver of DC
activation in AS01. Twenty-four hours after OVA/gE/AS01
immunization, CD40 expression was higher on cDC2s and inf-
cDC2s compared to cDC1s (Figure 2A), while CD86was higher on
cDC1s and cDC2s as compared to inf-cDC2s (Figure 2B). Finally,
to assess the individual contribution of the different subsets in Ag
presentation,we sorted the subsets from thedLN24hpiwithOVA/
AS01 andmeasured their ability to present endogenously processed
OVAprotein to cognate naiveCD4+ andCD8+T cells ex vivo. After
3 days of co-culture at differentDC:T cell ratios, cDC1s, cDC2s, and
inf-cDC2s all induced the proliferation ofOTI cells (Figures 2C,D,
Figure2D showingCTVprofiles at 1:4DC:Tcell ratio).Conversely,
cDC2s and inf-cDC2s were more efficient in inducing OTII cell
proliferationcompared tocDC1safter4daysof culture (Figures2E,
F, Figure 2F showing CTV profiles at 1:1 DC:T cell ratio). Thus, all
subsets of cDCs, including inf-cDC2s become proficient at
presenting AS01-adjuvanted model antigens.
Depletion of CD11c+ Cells In Vivo
Abrogates Cellular Responses to AS01-
Adjuvanted Vaccines
To examine the non-redundant role of CD11c+ cells, such as cDCs
and MCs, in mounting the adaptive immune response, weJanuary 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2smeasureddifferent aspects of the immune response afterDiphtheria
toxin (DT)-mediated CD11c+ cell depletion. CD11c+ cell depletion
was achieved by injecting DT into animals that had bone marrow
transplants from mice transgenic for DTR driven by the Itgax
promotor, driving expression of CD11c (Figure 3A) (27, 34, 35).
DTR transgene expression rendered CD11c+ cells sensitive to the
lethal effect of DT, while the bone marrow chimerism eliminated
off-target DT toxicity in the colon of intact Itgax-DTRmice. In the
absence of DT, immunization with AS01-adjuvanted vaccines in
these chimericmice led to an increaseofall cDCsubsets,monocytes,
and neutrophils after 24 h, as expected (Figures 3B–D). The i.m.Frontiers in Immunology | www.frontiersin.org 5injection of DT 12 h before OVA/gE/AS01 immunization
abrogated the accumulation of cDCs (Figure 3B) and monocytes
(Figure 3C) in the dLN 24 h post-immunization, while neutrophils
were less affected (Figure 3D). The reduced recruitment of
monocytes after DT-mediated CD11c+ cell depletion could be
related to their intermediate CD11c expression, or their
dependence on CD11chi cells, such as cDCs, for recruitment.
Next, we investigated whether CD11c+ cells were necessary for
the induction of antigen-specific T cells responses and antibodies.
Chimeric mice were immunized twice at d0 and d14 with OVA/gE






FIGURE 1 | cDC subsets are recruited to the draining lymph node after i.m. AS01 immunization. (A–D) Gating strategy of migratory MHCIIhi DC subsets pre-gated
on live CD3-CD19- cells (left panel) and pie charts depicting relative distribution of DC subset (right panel) in the dLN 24 h after i.m. (M. gastrocnemius) immunization
with 2 µg VZV gE antigen formulated in 1 µg AS01 (A), MPL (B), QS-21 (C), or buffer (D) per injection site. (E) Histograms showing surface expression of cDC,
monocyte and macrophage markers on different DC subsets in the dLN 24 h after i.m. immunization with gE/AS01 as in Figure 1A. (F) Absolute number of DC
subsets in the dLN 24 h after i.m. immunization with the different compounds as in Figures 1A–D. (G) Absolute number of total cells, cDCs, monocytes and
neutrophils in the dLN 24 h after i.m. immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. AS01, MPL, and QS-21 are all in
liposome. Data are representative of at least 2 independent experiments (n = 4–6 mice per group). Size of the pie chart is proportional to the absolute number of
DCs in the dLN (A–D). Error bars indicate mean ± SEM (G). Data analyzed with a Mann-Whitney test **p < 0.01.January 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2seachvaccinedose (Figure 3E). DTadministration at -12 h led to the
depletion of all three major cDC subsets in the dLN (Figure 3B).
Mice depleted of CD11c+ cells before or after immunization with
OVA/gE/AS01 failed to mount an antigen-specific CD8+ T cell
response when compared to immunized mice not receiving DT
treatment, as measured by the complete absence of OVA257–264-
tetramer positive CD8+ T cells in the blood (Figure 3F) or in the
spleen (Figure3G), or IFN-g/IL-2productionbyOVArestimulated
CD8+ splenocytes. (Figure 3H). We also measured cytokine
responses upon stimulation with VZV gE peptide pool by CD4+
T cells in the spleen at day 21. Interferon-g and IL-2 cytokine
production by CD4+ T cells was reduced in mice depleted of
CD11c+ cells, only when DT was administered before OVA/gE/
AS01 administration, but not 24 h later, suggesting that priming of
CD4+ T cells by CD11c+ cells occur mainly within 24 h after
immunization (Figure 3I). Finally, the increase in anti-gE IgGFrontiers in Immunology | www.frontiersin.org 6titers inmice immunized with AS01-adjuvanted vaccine compared
tonon-adjuvantedgroupwas reduced inDT-treatedmice, although
this was not reaching statistical significance (Figure 3J). Overall,
these data point to a crucial role of CD11c+ cells in the induction of
cellular immune responses driven by AS01.
CCR2- and Flt3-Dependent Cells Are
Required for Adaptive Immunity to AS01-
Adjuvanted Vaccines
The experiments in Itgax-DTRmice did not dissect which CD11c+
APC subsets was required for the adjuvant effect. MCs are typically
defined by their dependency on the chemokine receptor CCR2,
which is needed for egress of Ly6Chi monocytes from the bone
marrow. As a consequence, all of the monocyte progeny would be
disadvantaged in Ccr2-/-mice, compared with WTmice, as seen in




FIGURE 2 | AS01 activated cDCs effectively prime antigen-specific T cells. (A, B) Expression of CD40 (A) and CD86 (B) shown as MFIs by cDC subsets in the dLN
24 h after i.m. (M. gastrocnemius) immunization with OVA/gE antigen (0.5/2.5 µg) formulated in 2.5 µg AS01, MPL, QS-21, or buffer per injection site. AS01, MPL,
and QS-21 are all in liposome. Data analyzed with Two-way ANOVA and Tukey’s multiple comparisons test. Data are representative of at least two independent
experiments (n = 5 mice per group). **p < 0.01, ns, non-significant. (C) Expansion index of CD8+ OVA-specific TCR transgenic T cells (OTI) cocultured for 3 days
with the different migratory cDC subsets sorted from pooled dLNs (n = 80 mice) 24 h after i.m. immunization with OVA/AS01 (5/1 µg) per injection site.
(D) Proliferation prolife of CTV-labeled OTI T cells cocultured in 1:4 DC:T cell ratio with the different migratory cDC subsets for 3 days sorted from pooled dLNs
(n = 80 mice) 24 h after i.m. immunization with OVA/AS01 (5/1 µg) per injection site. (E) Expansion index of CD4+ OVA-specific TCR transgenic T cells (OTII)
cocultured for 4 days with the different migratory cDC subsets sorted from pooled dLNs (n = 80 mice) 24 h after i.m. immunization with OVA/AS01. (5/1 µg) per
injection site (F) Proliferation prolife of CTV-labeled OTII T cells cocultured in 1:1 DC:T cell ratio with the different migratory cDC subsets for 4 days sorted from
pooled dLNs (n = 80 mice) 24 h after i.m. immunization with OVA/AS01 (5/1 µg) per injection site.January 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2sIn addition, subtypes of tissue-cDC2s can also depend on CCR2
(37), especially during inflammation (23, 38). We therefore probed
for the cell intrinsic role of CCR2 on cDC subsets in mice
immunized with AS01-adjuvanted vaccines. In the dLN 24 h after
OVA/gE/AS01 i.m. injection in WT : Ccr2-/- mixed BM chimeras
(Figure 4A), cDC1s and cDC2s derived equally well from both
donor BMcompartments, whereas inf-cDC2swere generatedmore
efficiently from theWT BM component (Figure 4B). As a positive
control, monocytes were also mainly derived from the WT BM
component. We therefore confirmed that monocytes and inf-
cDC2s are the main subsets that are dependent on CCR2.
Flt3 is a hematopoietic cytokine receptor expressed by DC-
progenitors, and Flt3-/- mice lack all subsets of cDCs as well as
pDCs (18, 39). Comparisons of cDCs in Flt3-/- and Ccr2-/- mice can
thus provide valuable insights into which of the cDC subsets is
functionally required for AS01 adjuvant effect. As expected, Flt3-/-
micehad a significant reductionof total cDCnumber in thedLN24hFrontiers in Immunology | www.frontiersin.org 7pi with AS01-adjuvanted vaccine (Figure 4C; left panel). In line with
their pre-cDC origin this reduction was apparent for both cDC1 and
cDC2 subsets in Flt3-/-, while these subsets were numerically
conserved in Ccr2-/- mice (Figure 4D; left and middle panel).
Strikingly, inf-cDC2s were reduced in both Flt3-/- and Ccr2-/- mice
(Figure 4D; right panel). This is in line with previous work,
demonstrating that inf-cDC2s are Flt3L dependent pre-cDC-
derived cells that intrinsically depend on CCR2 (23). At the same
time, CCR2-dependent monocytes were also reduced in immunized
Flt3-/- mice, which could indicate that Flt3-dependent DCs are
indirectly required for the recruitment of monocytes and
monocyte-derived cells. Increase in neutrophil numbers in dLN
after AS01 vaccination was not altered in both Flt3-/- and Ccr2-/-
immunized mice (Figure 4C; right panel).
As specific tools to target inf-cDC2s are currently not available,
we next compared the adaptive immune responses between WT






FIGURE 3 | Cellular and humoral adaptive immune responses depend on CD11c+ cells. (A) Schematic representation of Itgax-DTR BM chimeras. (B–D) Absolute number
of distinct cDC subsets (B), monocytes (C), and neutrophils (D) in the dLN 24 h after i.m. immunization with OVA/gE/AS01 (0.5/2.5/2.5 µg) per injection site with or without
prior DT-mediated depletion of CD11c+ cells. (E) Schematic representation of Itgax-DTR BM chimeras treated 12 h prior to or 24 h after OVA/gE/AS01 (0.5/2.5/2.5 µg) per
injection site for both sensitization and challenge. (F, G) Percentage OVA257–264 MHCI-Tetramer
+ CD8+ T cells in the blood (F) and spleen (G) of Itgax-DTR BM chimeric mice
21 days after i.m. immunization at d0 and challenge at d14 with OVA/gE/AS01 (0.5/2.5/2.5 µg) per injection site and DT treatment. (H) Percentage IFN-g and/or IL2
producing CD8+ T cells upon OVA restimulation in the spleen of Itgax-DTR BM chimeric mice 21 days after i.m. immunization at d0 and challenge at d14 with OVA/gE/AS01
(0.5/2.5/2.5 µg) per injection site and DT treatment. (I) Percentage IFN-g and/or IL2 producing CD4+ T cells upon VZV gE restimulation in the spleen of Itgax-DTR BM
chimeric mice 21 days after i.m. immunization at d0 and challenge at d14 with OVA/gE/AS01 (0.5/2.5/2.5 µg) per injection site and DT treatment. (J) Total VZV gE specific
IgG levels in the serum of Itgax-DTR BM chimeric mice 21 days after i.m. immunization at d0 and challenge at d14 with OVA/gE/AS01 (0.5/2.5/2.5 µg) per injection site and
DT treatment. Data are representative of 4 independent experiments (n = 2–5 mice per group). Error bars indicate mean ± SEM (B–J). Data analyzed with a One-way
ANOVA and Sidak’s multiple comparison test *p < 0.05, **p < 0.01, ns, non-significant.January 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2stargeted andCcr2-/-mice inwhichmainly inf-cDCs,monocytes and
MCs will be targeted. The induction of OVA257–264-tetramer
positive CD8+ T cells was strongly inhibited in Flt3-/- mice and to
a lesser extent inCcr2-/-mice 7 days after a seconddose ofOVA/gE/Frontiers in Immunology | www.frontiersin.org 8AS01 (set-up as inFigure 3EwithoutDT treatment) (Figure 4E). A
similar pattern was observed whenmeasuring cytokine production
by CD8+ T cells upon OVA restimulation of splenocytes. (Figure









FIGURE 4 | Both Flt3 and CCR2 dependent cells are required for optimal adaptive response driven by AS01. (A) Schematic representation of CD45.1 WT: CD45.2
Ccr2-/- BM chimeras. (B) Normalized CD45.1/CD45.2 ratio relative to B cells of cell subsets in the dLN 24 h after i.m. immunization with OVA/gE/AS01 (0.5/2.5/2.5
µg) per injection site. (C) Absolute number of total cDCs, monocytes and neutrophils in the dLN of WT, Flt3-/-, and Ccr2-/- mice 24 h after i.m. immunization with
OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. (D) Absolute number of different cDC subsets in the dLN of WT, Flt3-/-, and Ccr2-/- mice
24 h after i.m. immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. (E) Percentage OVA257–264 MHCI-Tetramer
+ CD8+ T cells
in the spleen of WT, Flt3-/-, and Ccr2-/- mice 21 days after i.m. immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. Same
set-up as in Figure 3E without DT treatment. (F) Percentage IFN-g and/or IL2 producing CD8+ T cells upon OVA restimulation in the spleen of WT, Flt3-/-, and
Ccr2-/- mice 21 days after i.m. immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. Same set-up as in Figure 3E without DT
treatment. (G) Percentage IFN-g and/or IL2 producing CD4+ T cells upon VZV gE restimulation in the spleen of WT, Flt3-/-, and Ccr2-/- mice 21 days after i.m.
immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. Same set-up as in Figure 3E without DT treatment. (H) Total VZV gE
specific IgG levels in the serum of WT, Flt3-/-, and Ccr2-/- mice 21 days after i.m. immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per
injection site. Same set-up as in Figure 3E without DT treatment. (I–M) Cytokine and chemokine levels in serum of WT, Flt3-/-, and Ccr2-/- mice 24 h after i.m.
immunization with OVA/gE (0.5/2.5 µg) formulated in 2.5 µg AS01 or buffer per injection site. Shown individually for CXCL9 (J), CXCL10 (K), CCL2 (L), and IFN-g
(M). (A–M) Data are representative of 4 independent experiments (n = 2–5 mice per group). Error bars indicate mean ± SEM. Data analyzed with a Two-way ANOVA
(B–D) or One-way ANOVA (E–M) and Sidak’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ns, non-significant.January 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2sFlt3-/- compared toCcr2-/-mice, it appears that the preserved cDC1s
and cDC2s in Ccr2-/- mice can still induce some CD8+ T cell
responses, whereas CCR2-dependent inf-cDC2s or MCs are still
required to achieve the maximal response. In contrast, CD4+
T cell and antibody responses were equally reduced in both Flt3-/-
and Ccr2-/- mice (Figures 4G, H). This indicates that an APC
subset that relies on both Flt3/Flt3L and CCR2, such as inf-cDC2s,
is contributing significantly to the activation and cytokine
production by CD4+ T cells and antibody responses
Chemokines and IFN-pathway related cytokines are rapidly
induced by AS01 at the injection site and dLN and early IFN
response plays an important role in the effect on CD4+ T cell
priming (27). Overall production of such pro-inflammatory
cytokines was significantly reduced in the serum of Flt3-/- and
Ccr2-/- mice, and in particular for IFN-dependent cytokines
CXCL9 and CXCL10 (Figures 4I–K). Those cytokines are
known to recruit lymphocytes via CXCR3 interaction and are
associated with efficient induction of cellular immune responses
(40). Furthermore, the ligand for CCR2, i.e. CCL2, was reduced
in the serum of Flt3-/- immunized mice (Figure 4L), pointing to a
role of DCs in the chemotaxis of CCR2-dependent cells. The
prototypical Th1 cytokine IFN-g was barely detectable in serum
of both immunized Flt3-/- and Ccr2-/- mice (Figure 4M), whereas
it was induced in AS01-immunized WT mice.
In conclusion, these results indicate that the adaptive immune
responses induced by AS01-adjuvanted vaccines depend on cells
that require both Flt3/Flt3L and CCR2.
DISCUSSION
In line with our previous work, we show here that the adjuvant
system AS01 strongly impacts the innate immune response and
leads to a substantial influx of activated cDCs 24 h pi to the dLN in
mice (27). When tested separately, this immune enhancing effect
was mainly mediated by MPL in AS01. In addition to inducing
recruitment of cDC1s and cDC2s to the draining lymphnode,AS01
also promoted recruitment of inf-cDC2s, a recently discovered pre-
cDCderived cell typewhose induction depends on type I IFN, Flt3L
andCCR2 in vivo (23).Given the hybrid features of inf-cDC2s, such
as the expression of Ly6C and activating Fc receptors CD64 and
MAR-1, these cells have been misclassified as migratory MCs with
APC capacity in earlier studies (25, 27, 41). However, true
monocyte-derived MCs were barely detected within the
migratory DC pool in the dLN of AS01 immunized mice after
24 h and therefore are unlikely to contribute significantly in T cell
priming. In contrast, using an ex vivo antigen presentation assay
24 h after OVA/AS01 vaccination, we showed that cDC2s and inf-
cDC2s are capable and equally efficient at priming both OVA-
specific CD4+ and CD8+ T cells. Although we did not test this
experimentally yet, we predict that inf-cDC2s could play an even
more dominant role at time of a subsequent vaccination once
antigen-specific antibodies are present and could promote the
engulfment of opsonized antigen through Fc receptors expressed
on inf-cDC2s. It is indeed known that antibodies can aid in
the delivery of antigens to Fc-receptor bearing APCs in a process
appreciated as the vaccinal effect (42) and that expression ofFrontiers in Immunology | www.frontiersin.org 9high-affinity Fc receptors on inf-cDC2s direct antibody-
complexed antigen in a very effective way to these cells (23).
Using an in vivo Itgax-DTR depletion model, we have
demonstrated that CD11c+ cells play a non-redundant role in the
elicited adaptive immune response driven by AS01. Depletion of
CD11c+ cells prior to OVA/gE/AS01 immunization indeed
abolished both CD4+ and CD8+ antigen-specific T cell responses,
while depletion of DCs 24 h pi affected CD8+ but not CD4+ T cell
responses. This is in line with previous observations showing that
AS01 adjuvant effect is dramatically reduced, when the antigen is
given 24h afterAS01 administration, and inparticularCD4+T cells
(27). Demonstrating the relative and non-redundant contribution
of the individual cDC subsets in the induction of adaptive responses
remains nevertheless challenging. Transgenic mouse lines which
allow for selective depletion of DC subsets exist for cDC1s (e.g.
Xcr1-Cre x Irf8fl/fl orXcr1-DTR), but are currently lacking for (inf-)
cDC2s, given theoverlap ingenes between (inf-)cDC2s andMCs. In
the future, the development of new transgenic mouse lines using
dual cassettes targeting non-overlapping gene modules between
distinct cell subsets can help overcome current limitations.
We also found that antibodies were only partially affected in
the absence of DC subsets, despite of a reduction in T cells.
Similarly, mice lacking IFN-g or depleted in NK cells have a
profound reduction in cytokine production by antigen-specific
CD4+ T cell promoted by AS01 but the impact of antibodies was
limited (9). Therefore, additional pathways, involving direct B
cell activation, may be involved in antibody production,
independent of DC subsets and polyfunctional T cells.
Conventional DCs typically depend on Flt3/Flt3L (19), while
dependency on CCR2 is widely used to define monocyte descent
(26). Consequently, several papers have used Ccr2-/- mice to show
that monocyte-derived progeny contributes functionally to a given
phenotype (43–48). However, it has been shown that certain cDC2
subtypes also intrinsicallydependonCCR2formigrating into tissue
(37), especially during inflammation, and therefore CCR2-
dependency of a response cannot be considered equal to
monocyte-dependency (23, 25, 38). Whereas AS01 immunized
Ccr2-/- mice had particularly reduced numbers of inf-cDC2s, all
cDC subsets were equally reduced in the dLN of Flt3-/- mice.
Consequently, Flt3-/- mice mounted very poor antigen-specific
effector responses to the extent of what was observed in the
CD11c+ cell depleted mice. Despite normal numbers of cDC1s
and cDC2s, Ccr2-/- mice failed to raise normal levels of antigen-
specific antibodies after boost, and induceproperCD4+andCD8+T
cell responses. Since CCR2-dependent MCs poorly migrate to the
dLN after AS01 injection and have inert APC functions in other
systems when carefully separated from inf-cDC2s (23), the
dependency of inf-cDC2s on CCR2 offers a more plausible
explanation why Ccr2-/- mice have impaired Th1 cell-mediated
responses after immunization with AS01-adjuvanted vaccine and
increased susceptibility to viral infections (36, 43, 44). In an attempt
to experimentally prove the discrepancy between inf-cDC2s and
MCs, we tried to directly probe for the APC capacity of MCs but
were not able to sort enough MCs from the dLN of AS01
immunized mice. We would like to state that we do not exclude
any role of monocytes or MCs in AS01 adjuvanticity. Here, weJanuary 2021 | Volume 11 | Article 606805
Bosteels et al. AS01 Activity Relies on inf-cDC2sconclude that MCs are unlikely to substitute the role of bona fide
cDCs in priming naive lymphocytes after AS01 adjuvanted
vaccination in vivo since MCs poorly migrate to the dLN and fail
to prime naive T cells ex vivo. We cannot exclude that since they
mostly reside in tissues, MCs could serve as an APC orchestrating
the local reactivation or differentiation of previously primed
lymphocytes migrating in inflamed tissue.
We have previously shown that type I IFN-dependent
chemokines CXCL9 and CXCL10 are mainly produced by inf-
cDC2s (23). In line with this, these chemokines were reduced in
both Flt3-/- and Ccr2-/-AS01 immunized mice, and we propose this
is mainly caused by the reduction of inf-cDC2s in these mice. The
expression of these chemokines by inf-cDC2s may even further
enhanceTh1 responses (40, 49), explaining inpartwhy intracellular
IFN-g/IL-2 production was defective in CD4+ and CD8+ T cells
of AS01-immunized Ccr2-/- and Flt3-/- mice. Moreover, the
prototypical Th1 cytokine IFN-g, was also reduced in serum of
Flt3-/- and Ccr2-/-mice compared to wild-type counterparts 24 h pi
with AS01. Finally, the chemokine ligand CCL2 (or MCP-1), the
best-known ligand for CCR2, was reduced in the serum of Flt3-/-
immunized mice, pointing to a role of DCs in the chemotaxis of
CCR2 dependent cells, such as inf-cDC2s and monocyte-derived
cells. The reduced production of this chemokine could explain the
reduction of monocyte accumulation in the dLN of DC-depleted
Itgax-DTR mice and Flt3-/- mice. This is in line with our previous
work indicating that DCs can be an important source of CCL2 for
monocyte recruitment early in the induction of an adaptive
immune response (50).
Intrinsic type I IFN signaling on cDCs is required for the
development, activation, and maturation of inf-cDC2s in vivo. In
addition, the induction of Fc receptors on BM cDC2s cultured in
Flt3L and stimulated by lipopolysaccharide (LPS), a TLR4
agonist like MPL, was dependent on a type I IFN autocrine
loop (23). Similar effects could be elicited using IFN-g. Therefore
future experiments should address whether inf-cDC2s, and the
adaptive immune response in general, elicited by AS01 critically
depends on type I or II IFN signaling, particularly since AS01 has
been shown to elicit an early interferon signature, shown to play
a role in the induction of polyfunctional CD4+ T cells in mice (9,
51). This might have implications for patients with impaired IFN
responses such as elderly and diabetics (52, 53), which are highly
vulnerable for viral infections such as COVID-19 (54, 55). Yet it
seems that AS01 is able to overcome this impairment since the
AS01-adjuvanted recombinant Zoster vaccine is able to induce a
sustained cell-mediated responses in older adults (56).
Finally, a hybrid inflammatory DC subset, called DC3, was
recently identified in humans with shared characteristics
between type 2 DCs and monocytes (such as FcϵRI, CD14,
CCR2 and CD64) (57–60). These DC3s also secreted high
levels of Th1 cell-polarizing cytokines (e.g. IL-12) and T cell-
attracting chemokines (e.g. CXCL9 and CXCL10) (58) and,
unlike monocytes or monocyte-derived cells, efficiently
activated naïve T cells into IFN-g producing effector cells. In
addition, DC3s excelled in the induction of tissue-resident
memory T (TRM) cells (58), which are a hallmark of
protective anti-viral immunity induced by vaccination (61).Frontiers in Immunology | www.frontiersin.org 10Future studies in humans will have to address whether new
adjuvant systems like AS01 also work by eliciting these potent
functions of hybrid DC3s. Altogether recently defined murine
inf-cDC2s and human DC3s, in addition to cDC1s and cDC2s,
seem to play a crucial role in tissue immunity which defines them
as promising targets for vaccines.DATA AVAILABILITY STATEMENT
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